Brief: AIM ImmunoTech Provides Progress on Advancement of Ampligen Clinical Program for Treatment of Pancreatic Cancer
12/04/2022 13:00
April 12 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH PROVIDES PROGRESS ON ADVANCEMENT OF
AMPLIGEN®
CLINICAL DEVELOPMENT PROGRAM FOR THE TREATMENT OF PANCREATIC
CANCER
* AIM IMMUNOTECH INC - ON TRACK TO COMMENCE PHASE 2 STUDY OF
AMPLIGEN IN ADVANCED PANCREATIC CANCER IN Q3 2022
* AIM IMMUNOTECH INC - ENGAGES AMAREX CLINICAL RESEARCH LLC
TO
CONDUCT UPCOMING PHASE 2 STUDY
* AIM IMMUNOTECH INC - AMPLIGEN SHOWED PROMISING ACTIVITY AS
POTENTIAL MAINTENANCE THERAPY AFTER SYSTEMIC CHEMOTHERAPY
Source text for Eikon: ID:nGNX6mjygz
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential